JP2016516026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516026A5 JP2016516026A5 JP2015562529A JP2015562529A JP2016516026A5 JP 2016516026 A5 JP2016516026 A5 JP 2016516026A5 JP 2015562529 A JP2015562529 A JP 2015562529A JP 2015562529 A JP2015562529 A JP 2015562529A JP 2016516026 A5 JP2016516026 A5 JP 2016516026A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ethoxy
- acetamide
- oxo
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amino - Chemical class 0.000 claims 55
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 26
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- QXALUNHYJJONQH-UHFFFAOYSA-N 1,1,1-trifluoro-2-methylpropane Chemical compound CC(C)C(F)(F)F QXALUNHYJJONQH-UHFFFAOYSA-N 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 3
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical group C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- VTERPIWNZWWGKL-UHFFFAOYSA-N 2-[4-(3-ethoxy-2-oxo-3H-pyridin-5-yl)-2,3-difluorophenyl]-N-[4-(2-hydroxyethoxy)-3-(trifluoromethyl)phenyl]acetamide Chemical compound CCOC1C=C(C=NC1=O)c1ccc(CC(=O)Nc2ccc(OCCO)c(c2)C(F)(F)F)c(F)c1F VTERPIWNZWWGKL-UHFFFAOYSA-N 0.000 claims 1
- ISJKEAZUGHQANT-UHFFFAOYSA-N 2-[4-(3-ethoxy-2-oxo-3H-pyridin-5-yl)-2-fluorophenyl]-N-[6-(2-hydroxypropan-2-yl)-5-(trifluoromethyl)pyridin-3-yl]acetamide Chemical compound CCOC1C=C(C=NC1=O)c1ccc(CC(=O)Nc2cnc(c(c2)C(F)(F)F)C(C)(C)O)c(F)c1 ISJKEAZUGHQANT-UHFFFAOYSA-N 0.000 claims 1
- FYJMXDYOAPYOGN-UHFFFAOYSA-N 2-[4-(4-ethoxy-6-oxo-1h-pyridin-3-yl)-2-fluorophenyl]-n-[4-(2-hydroxyethoxy)-3-(trifluoromethyl)phenyl]acetamide Chemical compound CCOC1=CC(=O)NC=C1C(C=C1F)=CC=C1CC(=O)NC1=CC=C(OCCO)C(C(F)(F)F)=C1 FYJMXDYOAPYOGN-UHFFFAOYSA-N 0.000 claims 1
- JCFIOJFQCYYBQH-UHFFFAOYSA-N 2-[4-(5-ethoxy-6-oxo-1h-pyridin-3-yl)-3-fluorophenyl]-n-[4-(3-hydroxy-2,2-dimethylpropyl)-3-(trifluoromethyl)phenyl]acetamide Chemical compound N1C(=O)C(OCC)=CC(C=2C(=CC(CC(=O)NC=3C=C(C(CC(C)(C)CO)=CC=3)C(F)(F)F)=CC=2)F)=C1 JCFIOJFQCYYBQH-UHFFFAOYSA-N 0.000 claims 1
- LOOYDAFVHQHKCW-UHFFFAOYSA-N 3-ethoxy-1h-pyridin-2-one Chemical compound CCOC1=CC=CN=C1O LOOYDAFVHQHKCW-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- HWLZVEZNJOIQQY-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-ethoxy-6-oxopiperidin-3-yl)-2-fluorophenyl]acetamide Chemical compound CCOC1CC(CNC1=O)c1ccc(CC(=O)Nc2ccc(Cl)c(c2)C(F)(F)F)c(F)c1 HWLZVEZNJOIQQY-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- UHEIXBWQHRWKCW-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-[4-(5-ethoxy-6-oxo-1h-pyridin-3-yl)-2-fluorophenyl]acetamide Chemical compound N1C(=O)C(OCC)=CC(C=2C=C(F)C(CC(=O)NC=3C=C(Cl)C(Cl)=CC=3)=CC=2)=C1 UHEIXBWQHRWKCW-UHFFFAOYSA-N 0.000 claims 1
- YJSQUYQAEQTJDA-UHFFFAOYSA-N n-[4-cyano-3-(trifluoromethyl)phenyl]-2-[4-(5-ethoxy-6-oxo-1h-pyridin-3-yl)-2-fluorophenyl]acetamide Chemical compound N1C(=O)C(OCC)=CC(C=2C=C(F)C(CC(=O)NC=3C=C(C(C#N)=CC=3)C(F)(F)F)=CC=2)=C1 YJSQUYQAEQTJDA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 *NC(Cc(cc1)ccc1C(C=C1)=CNC1=O)=O Chemical compound *NC(Cc(cc1)ccc1C(C=C1)=CNC1=O)=O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013072683 | 2013-03-15 | ||
| CNPCT/CN2013/072683 | 2013-03-15 | ||
| CNPCT/CN2013/090059 | 2013-12-20 | ||
| CN2013090059 | 2013-12-20 | ||
| CN2014072449 | 2014-02-24 | ||
| CNPCT/CN2014/072449 | 2014-02-24 | ||
| PCT/IB2014/059817 WO2014141187A1 (en) | 2013-03-15 | 2014-03-14 | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516026A JP2016516026A (ja) | 2016-06-02 |
| JP2016516026A5 true JP2016516026A5 (enExample) | 2017-04-13 |
Family
ID=50390154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562529A Pending JP2016516026A (ja) | 2013-03-15 | 2014-03-14 | Ｒｅａｒｒａｎｇｅｄｄｕｒｉｎｇｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）キナーゼ阻害剤としてのピリジン誘導体 |
Country Status (33)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| US20170283404A1 (en) * | 2014-09-08 | 2017-10-05 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
| RS58813B1 (sr) * | 2014-09-10 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
| MX381233B (es) | 2014-09-10 | 2025-03-12 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret). |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP3371171B1 (en) | 2015-11-02 | 2023-10-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| ES2904615T3 (es) | 2016-03-16 | 2022-04-05 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones al respecto |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| MX2018013885A (es) | 2016-05-13 | 2019-08-16 | Inst De Medicina Molecular Joaeo Lobo Antunes | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP2020519672A (ja) | 2017-05-15 | 2020-07-02 | ブループリント メディシンズ コーポレイション | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| TWI876442B (zh) * | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| CN109096264B (zh) * | 2018-08-28 | 2019-08-23 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| AU2020257301B2 (en) | 2019-04-18 | 2025-10-23 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof |
| CN117903123A (zh) * | 2020-02-20 | 2024-04-19 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
| TWI777509B (zh) * | 2020-04-27 | 2022-09-11 | 美商美國禮來大藥廠 | 用於抑制ret激酶之化合物 |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
| ES3032873T3 (en) * | 2020-11-06 | 2025-07-28 | Lilly Co Eli | Pyrazole derivatives as ret kinase inhibitors |
| JP2024522938A (ja) | 2021-06-03 | 2024-06-21 | フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド | 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位 |
| CN115626880B (zh) * | 2022-11-15 | 2023-11-14 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
| EP4650002A1 (en) * | 2024-05-15 | 2025-11-19 | Ludwig-Maximilians-Universität | Aniline-based modulators of the nuclear receptor tlx (nr2e1) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053476B (en) | 1999-08-12 | 2005-03-25 | Upjohn Co | 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents |
| US20040019046A1 (en) * | 2000-11-27 | 2004-01-29 | Paolo Pevarello | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| MX2009003985A (es) * | 2006-10-16 | 2009-04-27 | Novartis Ag | Fenil-acetamidas utiles como inhibidores de cinasa de proteina. |
| EP2099774A4 (en) * | 2006-11-15 | 2010-11-24 | Ym Biosciences Australia Pty L | INHIBITORS OF KINASEACTIVITY |
| BR112012003661A2 (pt) * | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| AR095308A1 (es) | 2013-03-15 | 2015-10-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento |
-
2014
- 2014-03-14 AU AU2014229233A patent/AU2014229233B2/en not_active Ceased
- 2014-03-14 SI SI201430170A patent/SI2970191T1/sl unknown
- 2014-03-14 EA EA201591738A patent/EA029296B1/ru not_active IP Right Cessation
- 2014-03-14 CA CA2905627A patent/CA2905627A1/en not_active Abandoned
- 2014-03-14 BR BR112015023618A patent/BR112015023618A2/pt not_active IP Right Cessation
- 2014-03-14 PL PL14713598T patent/PL2970191T3/pl unknown
- 2014-03-14 DK DK14713598.2T patent/DK2970191T3/en active
- 2014-03-14 WO PCT/IB2014/059817 patent/WO2014141187A1/en not_active Ceased
- 2014-03-14 HR HRP20170363TT patent/HRP20170363T1/hr unknown
- 2014-03-14 TW TW103109315A patent/TW201524958A/zh unknown
- 2014-03-14 JP JP2015562529A patent/JP2016516026A/ja active Pending
- 2014-03-14 UY UY0001035465A patent/UY35465A/es unknown
- 2014-03-14 US US14/775,772 patent/US9382238B2/en not_active Expired - Fee Related
- 2014-03-14 PT PT147135982T patent/PT2970191T/pt unknown
- 2014-03-14 RS RS20170177A patent/RS55710B1/sr unknown
- 2014-03-14 SG SG11201506695UA patent/SG11201506695UA/en unknown
- 2014-03-14 NZ NZ628388A patent/NZ628388A/en not_active IP Right Cessation
- 2014-03-14 ME MEP-2017-60A patent/ME02664B/me unknown
- 2014-03-14 ES ES14713598.2T patent/ES2616655T3/es active Active
- 2014-03-14 EP EP14713598.2A patent/EP2970191B1/en active Active
- 2014-03-14 CN CN201480015907.3A patent/CN105051027A/zh active Pending
- 2014-03-14 SM SM20170152T patent/SMT201700152T1/it unknown
- 2014-03-14 PE PE2015001878A patent/PE20151538A1/es not_active Application Discontinuation
- 2014-03-14 MX MX2015012286A patent/MX2015012286A/es unknown
- 2014-03-14 LT LTEP14713598.2T patent/LT2970191T/lt unknown
- 2014-03-14 HU HUE14713598A patent/HUE033423T2/en unknown
- 2014-03-14 UA UAA201510041A patent/UA115264C2/uk unknown
-
2015
- 2015-09-03 IL IL241161A patent/IL241161A0/en unknown
- 2015-09-08 CL CL2015002514A patent/CL2015002514A1/es unknown
- 2015-09-10 PH PH12015502044A patent/PH12015502044A1/en unknown
- 2015-09-14 CR CR20150490A patent/CR20150490A/es unknown
- 2015-09-15 DO DO2015000244A patent/DOP2015000244A/es unknown
-
2016
- 2016-06-02 US US15/171,229 patent/US9789100B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 CY CY20171100319T patent/CY1118730T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516026A5 (enExample) | ||
| ME02664B (me) | Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze | |
| JP2017538750A5 (enExample) | ||
| JP2013510859A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| JP2007519694A5 (enExample) | ||
| JP2016519685A5 (enExample) | ||
| JP2007519754A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2016536364A5 (enExample) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| JP2016536363A5 (enExample) | ||
| HRP20130969T1 (hr) | Spojevi spiropiperidona kao antagonisti receptora orl-1 | |
| JP2016530310A5 (enExample) | ||
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| RU2013112122A (ru) | Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы | |
| PE20180227A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| RU2016133626A (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| JP2017512786A5 (enExample) | ||
| HRP20130967T1 (hr) | Spojevi spiropiperidona kao antagonisti receptora orl-1 | |
| JP2013517279A5 (enExample) | ||
| PE20191792A1 (es) | Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos | |
| HRP20200606T1 (hr) | Derivati fenila kao agonisti kanabinoidnog receptora 2 | |
| JP2013525262A5 (enExample) |